Management and strategy consulting for life science companies
1/26/2012 – “Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies” by Brett Chase of Minyanville
1/5/2012 – “Dendreon reports spike in Provenge sales; shares soar” by Bill Berkrot of Reuters
10/11/2011 – “Nobel prize-winning science should incubate deals” by David Holley of The Deal
10/7/2011 – “Zytiga creeps up on Provenge prostate-cancer drug” by Ransdell Pierson of Reuters
8/23/2011 – “What’s a Cancer Drug Worth?” by Brett Chase of Minyanville
8/22/2011 – “With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers” by Emily Hayes of The Pink Sheet
8/17/2011 – “Daiichi Sankyo is poster company for sector ripe for M&A” by David Holley of The Deal Pipeline
8/4/2011 – “Dendreon plunges as Provenge prospects wither” by by Bill Berkrot of Reuters
8/4/2011 – “Dendreon’s Stock Plunges on Low Provenge Sales” by Brett Chase of Minyanville
February 2, 2012 – MD Becker Partners is proud to return as “PR Sponsor” for the 19th Annual BioNJ Meeting, Awards Program and Networking Event being held at the Hilton East Brunswick. Click here to view the video clip our firm produced with highlights from the past several years.
November 10, 2011 – “MD Becker Partners Celebrates Third Successful Year in Business” press release
October 6, 2011 – MD Becker Partners hosted its 2nd annual “Cancer Immunotherapy: A Long Awaited Reality” conference event in New York. For more information, please Click Here for the Event Website and for select video replays, visit the firm’s YouTube channel by clicking here.
June 30, 2011 – “Expert Roundtable Explores Recent Advances in Cancer Immunotherapy; Cancer Research Institute and MD Becker Partners Jointly Publish New Industry Report” press release
March 17-19, 2011 – MD Becker Partners participated in the Cancer Immunotherapy Consortium’s 2011 Scientific Colloquium, which took place in National Harbor, MD
Legal Disclaimer | © 2012MD Becker Partners LLC • Built on the Genesis Framework